The 2025 YouGov survey data from more than 31,000 US adults show significant support for recreational cannabis legalization, medical use, and federal reclassification.
|Sponsored|March 31, 2020
Epic C18 Cannabinoid
Author(s)ES Industries
The analysis of cannabinoid samples, to perform complete profiling of the various cannabis and hemp strains and more accurate potency testing, is becoming more essential. There are at least 100 identified cannabinoids that have been isolated from cannabis sativa. These minor cannabinoids can possibly interfere with the chromatography of the five most common cannabinoids: tetrahydrocannabinol (THC), delta-9-tetrahydrocannabinolic acid A (THCA), cannabidiol (CBD), cannabidiolic acid (CBDA), and cannabinol (CBN). ES Industries Inc. have developed a new C18 column – Epic C18 Cannabinoid to fully resolve the 11 major and most frequently observed minor cannabinoids using commercial standards. The baseline separation achieved with the Epic C18 Cannabinoid column ensures positive identification and accurate quantitation for the cannabinoids of interest. Epic C18 Cannabinoid is based on the robust Epic bonding chemistry developed by ES Industries. The superior performance of Epic C18 Cannabinoid is a product of high density bonding which has been achieved through refinements in the processes and catalyst development. High bonding density is one of the most important factors in producing a robust stationary phase and robust HPLC column. The 11 component cannabinoid analysis is achieved with Epic C18 Cannabinoid using a simple isocratic mobile phase which is more easily transferable between instruments/laboratories, compared to more complex methods that incorporate atypical mobile phase gradients or additives.
ES Industries
701 South Route 73
West Berlin, NJ 08091 USA
856-753-8400
Related to this article
Curaleaf is opening a new cannabis dispensary called Curaleaf Millcreek in Erie, Pennsylvania.
Learn how third-party audits enhance compliance in the cannabis industry, ensuring readiness for evolving regulations and fostering consumer trust.
Let’s take a look at the 2025 cannabis coverage on medical cannabis research and medicine to catch up on industry trends and innovations.
Let’s take a look at the 2025 cannabis coverage on cannabis research to catch up on industry trends and innovations.
A lack of standards for cannabis vape devices puts consumers at risk, but several organizations are committed to the research, collaboration, and solutions needed to promote safety and quality in the industry.
Cannabis genetics fundamentally dictate the plant's potential for chemical signatures, including cannabinoid and terpene profiles, and physical traits, such as yield. Cultivators use selective techniques, such as "stacking," to enhance specific compounds. Ultimately, successful cultivation involves balancing superior genetics with environmental "levers" to optimize gene expression and create targeted strains.
It’s that time of year again—the Cannabis Science and Technology (CST) top 10 articles from the previous year. CST published a wide variety of content throughout 2025. Here is just a small snippet of some of the top articles that our readers enjoyed. See if any of your favorites made the list!